Biomarker Development: The Latest Breakthrough For Alzheimer's Disease

AD or Alzheimer's disease is the most common brain disorder especially on the stage of aging. According to research, there are estimated 35 million affected people all around the globe and still increasing each year. Today, treatment and diagnosis for this continues to soar high just like the neuropsychological tests that can detect AD problem whenever there are figured early symptoms. For the last decade, the research and study about AD had just started focusing on how it affects the brain. Great news that can lighten up the burden for Alzheimer's patients has finally released with the development of imaging-based biomarkers. How can it affect the diagnosis for Alzheimer's before setting any medication?

Today, there is an urgent need for reliable Alzheimer's diagnostic biomarkers for diagnosis and early detection of the said disease. Health experts from prestigious medical institution reveal that this special issue on diagnosing Alzheimer's disease is focused on latest trend of medical and scientifically identifying the AD diagnostic biomarkers with the latest imaging modalities.

This diagnosis is comparable to various MRI technologies or the Magnetic Resonance Imaging. It can diagnose AD as well monitor the progression of the disease within. Brian T. Gold used the diffusion tension imaging or the DTI to identify the development of the amnestic cognitive impairment or the MCI that can be the early symptoms of AD. Charles D. Smith illustrates the MRI detection for Alzheimer's disease as a key structural alteration. It can predict the possible memory impairment of the patient.

MRI can produce information about the brain's anatomy. The fMRI or the functional MRI can produce information significant information on the different region of the brain as well as its individual and specific function to the body. This can help medical experts to explore more the human brain and detect any changes made from the activity and the connectivity of the AD patient's brain. Monitoring the brain's function alteration activity in relation to the deficits of Alzheimer's has proven to be effective as the early diagnostic biomarker a review from D. Manda and some of his colleagues. Using the fMRI, this can positively study older individual's brain activity. Patients who have AD as they do cognitive task and while at rest has some functional changes.

The MRI is a powerful non-invasive used for imaging the brain. This technique can give important data about the neurochemical changes of the brain. These changes may give sign of early AD pathology and can help the diagnosis of patients who are going through on more advanced AD.

Imaging can also help fast examination on the molecular and therapeutic effects of AD treatments. Medical experts also found out that sufferers who have been medicated with donepezil for mild cases had a crucial increase in interhemispheric functional connectivity on the right and left dorsolateral prefrontal cortices. Dr. Giulia Liberati describes the MRI for AD as a brain-computer interface where it can detect the person's emotional stage and cognitive behavior. It can also provide information for drug affected person on how the brain is damaged and functioning under the influence of drugs.